US OptionsDetailed Quotes
AGEN250117C1500
- 0.06
- 0.000.00%
15min DelayClose Apr 8 09:59 ET
0.00High0.00Low
0.00Open0.06Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV-43.27%PremiumJan 17, 2025Expiry Date1.25Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma45.83Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Agenus Stock Discussion
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
1 minute ago, 4:30 AM PST
Via BusinessWire
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. T...
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanc...
No comment yet